On 27.11.2019, the team of project 2.21 arranged its official kick-off meeting! The multidisciplinary team of researchers and partners aims to develop and validate new small-molecule based imaging probes targeting the immune checkpoint axis PD-1/PD-L1 using PET. Hence, novel imaging derived biomarkers, which might be of major importance in several cancer entities, are expected within this project, lead by Wolfgang Wadsak in Vienna. Infrastructure as well as scientific expertise are jointly mobilized between CBmed, the scientific partners, Medical University and University of Veterinary Medicine Vienna, and the company partners, ITM (Munich, Germany) and SOFIE Bioscience (Los Angeles, USA).
We want to thank all participants for their active contribution to a very fruitful meeting. We are looking forward to constant progress, an inspiring cooperation and rewarding research outcomes. We’ll keep you updated!